Clinical Investigation to Evaluate the Safety, Tolerability and Performance of the Medicsen Smartpatch, a Non-Invasive Ultrasound-Based Drug Delivery Medical Device (SOUNDD Study)
| Registry | NCT07615959, acronym SOUNDD |
|---|
| Status | Active not recruiting |
|---|
| Phase | Not applicable |
|---|
| Study type | Interventional; randomized, crossover, masking: none, treatment |
|---|
| Enrollment | 30 (Actual) |
|---|
| Sponsor | Medicsensors S.L (Industry); collaborators: SmartBIO Analytics, Hospital Universitario Ramon y Cajal, Avania |
|---|
| Conditions | Healthy |
|---|
| Interventions | Medicsen Smartpatch, Subcutaneous (SC) single dose (Device) |
|---|
| Dates | start 2026-01-20, primary completion 2026-11-01 (estimated), completion 2026-11-01 (estimated), first posted 2026-05-29, last updated 2026-05-29 |
|---|
| Locations | 1 site in Spain |
|---|
Related Papers Related Patents Related Grants Related Experts
All trials for Healthy All trials of Medicsen Smartpatch All trials of Subcutaneous (SC) single dose
-Summary
The goal of this clinical trial is to understand the efficacy of Medicsen's Smartpatch to deliver drugs through the skin in healthy volunteers. The main questions it aims to answer are:
* Is the administration with Medicsen Smartpatch safe for the patient?
* Can Medicsen's Smartpatch be used to effectively administer drugs to patients?
Researchers will compare administration with Medicsen's Smartpatch with the subcutaneous administration of the drug to see if the efficacy and safety are comparable
Participants will be asked to fill a tolerability survey after receiving each of the two interventions: Subcutaneous administration and Medicse's Smartpatch.
Blood samples will be taken at different timepoints to asses for efficacy of each treatment.
Expand all sections · Collapse all
+Detailed description
The clinical investigation will be conducted in two stages:
Stage 1: A first-in-human pilot study to evaluate the safety, tolerability, and exploratory performance of the Medicsen Smartpatch for drug delivery in healthy volunteers: a single-center, open-label study.
Stage 2: A confirmatory study to evaluate the performance of the Medicsen Smartpatch by comparing sonophoresis with subcutaneous drug delivery: a randomized, single-dose, open-label, two-way crossover study in healthy volunteers.
Study subjects will be monitored for device-attributable adverse effects during the scheduled examinations and at any examinations resulting from study subjects' self-reported concerns. A licensed physician will review any unanticipated adverse events associated with the protocol.
+Arms and interventions
| Arm | Type | Interventions | Description |
|---|
| Sonophoresis | Experimental | Device: Medicsen Smartpatch | In the sonophoresis arm, the drug is administered to the volunteers through the application of ultrasound waves that increase the skin permeability. |
| Subcutaneous injection | Active comparator | Device: Subcutaneous (SC) single dose | In the subcutaneous injection arm, the drug is administered to the volunteers through means of subcutaneous injection. |
- Medicsen Smartpatch (Device): This intervention consists of administering the drug using the Medicsen Smartpatch, a non-invasive, needle-free drug delivery device that utilizes sonophoresis technology to enhance absorption through the skin.
- Subcutaneous (SC) single dose (Device): This intervention consists of administering the drug via standard subcutaneous injection using a pre-filled pen injector
+Outcome measures
Primary outcomes
- Stage 1 - Device-related adverse events (adverse device effects; ADEs) [Periprocedural]: Primary Outcome Measure of Stage 1.
Incidence and severity of ADEs is assesed, with special focus on those occurred at the site of administration and those leading to treatment interruption.
- Stage 1 - Assessment of local tolerability through questionnaires and visual examination [Periprocedural]: Primary Outcome Measure of Stage 1.
Subject-reported sensations (pain/burning, itching/stinging, discomfort) during and after administration are assesed through questionnaires.
Dermatologist-evaluated skin signs (erythema, edema, vesicles, crusts/exudate, scaling/lichenification, hematomas/bleeding, tenderness) are assesed through visual examination.
- Stage 2 - Area under the curve (AUC0-∞ and AUC0-t) [Prior intervention and 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 120, 180, 240 minutes post-dose]: Primary Outcome Measure of Stage 2
- Stage 2 - Peak plasma concentration (Cmax) [Prior intervention and 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 120, 180, 240 minutes post-dose]: Primary Outcome Measure of Stage 2
Secondary outcomes
- Stage 1 - Peak plasma concentration (Cmax) [Prior intervention and 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 120, 180, 240 minutes post-dose]: Secondary Outcome Measure of Stage 1.
- Stage 1 -Area under the curve (AUC0-∞ and AUC0-t) [Prior intervention and 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 120, 180, 240 minutes post-dose]: Secondary Outcome Measure of Stage 1.
- Stage 1 - Tmax and t1/2 [Prior intervention and 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 120, 180, 240 minutes post-dose]: Secondary Outcome Measure of Stage 1.
- Stage 1 - Time at which the device notifies that the full dose has been delivered. [Periprocedural]: Secondary Outcome Measure of Stage 1.
- Stage 2 - Tmax and t1/2 [Prior intervention and 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 120, 180, 240 minutes post-dose]: Secondary Outcome Measure of Stage 2.
- Stage 2 - Incidence and severity of ADEs [Periprocedural]: Secondary Outcome Measure of Stage 2.
- Stage 2 - Number of participants with treatment-emergent clinically significant abnormalities in laboratory parameters (hematology and biochemistry) [Through study completion]: Secondary Outcome Measure of Stage 2.
Number of participants with laboratory values outside the normal reference range that are considered clinically significant compared to baseline. This includes hematology (hemoglobin, hematocrit, Red blood cell, MCV, MCH, MCHC, White blood cell with differential, and platelets) and biochemistry (urea, creatinine, glucose, AST (SGOT), ALT (SGPT), GGT, ALP, and total bilirubin).
Unit of measure: Participants
- Stage 2 - Number of participants with treatment-emergent clinically significant abnormalities in vital signs. [Through study completion]: Secondary Outcome Measure of Stage 2.
Number of participants with vital sign values outside the normal reference range that are considered clinically significant compared to baseline. This includes Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), Heart Rate (HR), Respiratory Rate (RR), and Temperature (T) measured before and after the procedure.
Unit of measure: Participants
- Stage 2 - Number of participants with changes in electrocardiogram from baseline [Through study completion]: Secondary Outcome Measure of Stage 2.
A standard 12-lead ECG is performed with an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals before and after the procedure to determine changes from baseline values.
- Stage 2 - Assessment of local tolerability through questionnaires and visual examination [Periprocedural]: Secondary Outcome Measure of Stage 2.
Subject-reported sensations (pain/burning, itching/stinging, discomfort) during and after administration of both interventions are assesed through questionnaires.
Dermatologist- evaluated skin signs (erythema, edema, vesicles, crusts/exudate, scaling/lichenification, hematomas/bleeding, tenderness) after Medicsen Smartpatch intervention are assesed through visual examination.
- Stage 2 - Time at which the device notifies that the full dose has been delivered. [Periprocedural]: Secondary Outcome Measure of Stage 2
- Stage 2 - Usability endpoints (for healthcare professionals) [Immediately after the intervention]: Secondary Outcome Measure of Stage 2.
Rate of first-attempt success, time to complete setup, clarity of instructions, and user-reported ease-of-use scores for healthcare professionals are assesed through the Healthcare Proffesionals' Usability Questionnaire, in which a score from 1 to 5 is given to each of the measurements, and where a higher score means a worse outcome.
- Stage 2 - Usability endpoints (for patients) [Immediately after the intervention]: Secondary Outcome Measure of Stage 2.
Comfort and willingness to reuse the device are assesed through the Patient's Usability Questionnaire, in which a score from 1 to 5 is given to each of the measures, and where a higher score means a worse outcome.
+Eligibility
Sex: All, ages: 18 Years to 55 Years, accepts healthy volunteers
Inclusion Criteria:
* Subjects must provide signed informed consent prior to participation in any study related procedures
* Healthy Caucasian volunteers, any sex, aged between 18 to 55 years
* Body Mass Index (BMI) between 18.5 and 30.0 kg/m2
* Ability and agreement to comply with the study requirements
* Medical history and physical examination within normal limits.
* No clinically relevant abnormalities in hematology, biochemistry, virology, or urine tests.
* Participants who engage in sexual activity which could result in pregnancy for themselves or their partner(s) must agree to use highly effective methods of contraception during the clinical investigation.
Exclusion Criteria:
* Case history of hypersensitivity to medicinal products or any other allergic process that could interfere with study according to the investigator's judgement.
* Current relevant disease, including respiratory disease, cardiovascular, endocrine, neurological, haematological, renal, neoplasic, hepatopathy, dermatology, gastrointestinal distress, hypertension, or infectious acute processes that could interfere with study according to the investigator's judgement.
* Previous chronic processes or with rebound characteristics that could interfere with study according to the investigator's judgement.
* Administration of topic or systemic medication including medicinal plants within 14 days before the intervention.
* Presence of skin disorders or lesions at the intended application site (e.g., eczema, psoriasis, infections, open wounds), which may interfere with drug absorption or increase risk of adverse effects.
* Implanted electronic medical devices, such as pacemakers or neurostimulators, due to potential interference with ultrasonic energy.
* Pregnant or breastfeeding women, due to lack of safety data for either the drug or the ultrasound application in this population.
* Severe cognitive or motor impairment, where safe operation of the patch cannot be ensured, unless under continuous caregiver supervision.
+Locations (1)
| Facility | City | Country | Status |
|---|
| Hospital Universitario Ramon y Cajal | Madrid, Madrid | Spain | |
+Publications
- Mannocci A, De Carli G, Di Bari V, Saulle R, Unim B, Nicolotti N, Carbonari L, Puro V, La Torre G. How Much do Needlestick Injuries Cost? A Systematic Review of the Economic Evaluations of Needlestick and Sharps Injuries Among Healthcare Personnel. Infect Control Hosp Epidemiol. 2016 Jun;37(6):635-46. doi: 10.1017/ice.2016.48. Epub 2016 Mar 29. PMID 27022671
- Elder A, Paterson C. Sharps injuries in UK health care: a review of injury rates, viral transmission and potential efficacy of safety devices. Occup Med (Lond). 2006 Dec;56(8):566-74. doi: 10.1093/occmed/kql122. Epub 2006 Oct 25. PMID 17065314
- Aronson R. The role of comfort and discomfort in insulin therapy. Diabetes Technol Ther. 2012 Aug;14(8):741-7. doi: 10.1089/dia.2012.0038. Epub 2012 Apr 26. PMID 22537418
- Wagner J, Malchoff C, Abbott G. Invasiveness as a barrier to self-monitoring of blood glucose in diabetes. Diabetes Technol Ther. 2005 Aug;7(4):612-9. doi: 10.1089/dia.2005.7.612. PMID 16120035
- Jenkins K. II. Needle phobia: a psychological perspective. Br J Anaesth. 2014 Jul;113(1):4-6. doi: 10.1093/bja/aeu013. Epub 2014 Feb 25. No abstract available. PMID 24574504
- McLenon J, Rogers MAM. The fear of needles: A systematic review and meta-analysis. J Adv Nurs. 2019 Jan;75(1):30-42. doi: 10.1111/jan.13818. Epub 2018 Sep 11. PMID 30109720
- Schoellhammer CM, Polat BE, Mendenhall J, Maa R, Jones B, Hart DP, Langer R, Blankschtein D. Rapid skin permeabilization by the simultaneous application of dual-frequency, high-intensity ultrasound. J Control Release. 2012 Oct 28;163(2):154-60. doi: 10.1016/j.jconrel.2012.08.019. Epub 2012 Aug 23. PMID 22940128
- Barati AH, Mokhtari-Dizaji M, Mozdarani H, Bathaie Z, Hassan ZM. Effect of exposure parameters on cavitation induced by low-level dual-frequency ultrasound. Ultrason Sonochem. 2007 Sep;14(6):783-9. doi: 10.1016/j.ultsonch.2006.12.016. Epub 2007 Jan 23. PMID 17347019
- Tezel A, Sens A, Mitragotri S. Investigations of the role of cavitation in low-frequency sonophoresis using acoustic spectroscopy. J Pharm Sci. 2002 Feb;91(2):444-53. doi: 10.1002/jps.10024. PMID 11835204
- Mitragotri S, Blankschtein D, Langer R. Ultrasound-mediated transdermal protein delivery. Science. 1995 Aug 11;269(5225):850-3. doi: 10.1126/science.7638603. PMID 7638603
- Tachibana K. Transdermal delivery of insulin to alloxan-diabetic rabbits by ultrasound exposure. Pharm Res. 1992 Jul;9(7):952-4. doi: 10.1023/a:1015869420159. No abstract available. PMID 1438012
- Tachibana K, Tachibana S. Transdermal delivery of insulin by ultrasonic vibration. J Pharm Pharmacol. 1991 Apr;43(4):270-1. doi: 10.1111/j.2042-7158.1991.tb06681.x. PMID 1676740
- Williams AR. Phonophoresis: an in vivo evaluation using three topical anaesthetic preparations. Ultrasonics. 1990 May;28(3):137-41. doi: 10.1016/0041-624x(90)90075-y. PMID 2339470
- Levy D, Kost J, Meshulam Y, Langer R. Effect of ultrasound on transdermal drug delivery to rats and guinea pigs. J Clin Invest. 1989 Jun;83(6):2074-8. doi: 10.1172/JCI114119. PMID 2498396
- Bommannan D, Okuyama H, Stauffer P, Guy RH. Sonophoresis. I. The use of high-frequency ultrasound to enhance transdermal drug delivery. Pharm Res. 1992 Apr;9(4):559-64. doi: 10.1023/a:1015808917491. PMID 1495903
- Mitragotri S, Edwards DA, Blankschtein D, Langer R. A mechanistic study of ultrasonically-enhanced transdermal drug delivery. J Pharm Sci. 1995 Jun;84(6):697-706. doi: 10.1002/jps.2600840607. PMID 7562407
- Park D, Park H, Seo J, Lee S. Sonophoresis in transdermal drug deliverys. Ultrasonics. 2014 Jan;54(1):56-65. doi: 10.1016/j.ultras.2013.07.007. Epub 2013 Jul 16. PMID 23899825
- Polat BE, Hart D, Langer R, Blankschtein D. Ultrasound-mediated transdermal drug delivery: mechanisms, scope, and emerging trends. J Control Release. 2011 Jun 30;152(3):330-48. doi: 10.1016/j.jconrel.2011.01.006. Epub 2011 Jan 14. PMID 21238514
- Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000 Jun;9(3):165-9. doi: 10.1034/j.1600-0625.2000.009003165.x. PMID 10839713